hotspot -WSS

hotspot

author：explore 2025-09-07 11:08:59 - browse：2

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Bird flu makes raw milk dangerous to consume, mouse study finds

hotspot

focus

WSS

Biotech lab space demand falls sharply

Ozempic cut risk of death in diabetes patients with chronic kidney disease

J&J reports mixed data on next

Bird flu makes raw milk dangerous to consume, mouse study finds

Decentralized clinical trials need collaboration to achieve wider use

Bird flu makes raw milk dangerous to consume, mouse study finds

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why are Kaiser Permanente staff considering a strike?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senators: Long

State Dept. review finds Biden bears some blame for Afghanistan failures

Why are Kaiser Permanente staff considering a strike?

As demand for Covid shots wanes, Moderna seeks its next success

Bird flu makes raw milk dangerous to consume, mouse study finds

entertainment

EpiPen alternative approval delay highlights citizen petition issue

Lawsuit challenges CMS nursing home minimum staffing rule

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Hospitals need to get ahead of regulations on climate change

Lasker Awards 2023: Winners in biomedical research

Congress: Prevent baby formula shortages by passing a new bill

hotspot

hotspot

focus

explore